temozolomide has been researched along with Lymphopenia in 30 studies
Lymphopenia: Reduction in the number of lymphocytes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acute severe lymphopenia (ASL) frequently develops during radiation therapy (RT) and concurrent temozolomide (TMZ) for high-grade glioma (HGG) and is associated with decreased survival." | 7.81 | Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. ( Badiyan, SN; Campian, JL; Chicoine, MR; DeWees, TA; Dunn, G; Fergus, S; Huang, J; Kim, AH; Linette, G; Mullen, DF; Robinson, CG; Simpson, JR; Speirs, CK; Tran, DD, 2015) |
| "Malignant glioma patients treated with the golden standard therapy, focal radiotherapy plus concomitant daily temozolomide (radiotherapy/TMZ), often suffer severe lymphopenia." | 7.76 | Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment. ( Akutsu, H; Ishikawa, E; Matsumura, A; Nakai, K; Sakamoto, N; Takano, S; Tsuboi, K; Yamamoto, T, 2010) |
| "Temozolomide is utilized as a treatment for a variety of solid tumors and has been associated with the development of selective lymphopenia." | 7.74 | Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. ( Baden, LR; Kulke, MH; Michelini, A; Schwarzberg, AB; Sengupta, T; Stover, EH; Vincitore, M, 2007) |
| "The authors investigated the safety of 75 mg/m2 temozolomide for 21 days every 28 days in glioma patients." | 7.73 | Is protracted low-dose temozolomide feasible in glioma patients? ( Blatt, V; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Pasetto, L; Scopece, L; Tosoni, A, 2006) |
| "Standard schedule temozolomide (TMZ; daily for 5 days every 4 weeks) is often used in melanoma patients, but phase III data show that it is no more effective than standard dacarbazine." | 7.72 | Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. ( Chapman, PB; Foster, T; Krown, SE; Livingston, PO; Quinn, C; Sepkowitz, KA; Sohn, S; Su, YB; Williams, L; Wolchok, JD, 2004) |
| "There is no standard treatment for glioblastoma with elements of PNET (GBM-PNET)." | 5.43 | Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. ( Fersht, N; Mandeville, HC; Mycroft, J; O'Leary, B; Saran, F; Solda, F; Vaidya, S; Zacharoulis, S, 2016) |
| "Standard treatment for glioblastoma includes maximal safe resection followed by adjuvant radiation and concurrent temozolomide for 6 weeks, followed by 6 months of maintenance temozolomide; additionally, concurrent high doses of corticosteroids are required for many patients to reduce intracranial pressure and reduce inflammatory side effects." | 5.41 | Radiotherapy, lymphopenia and improving the outcome for glioblastoma: a narrative review. ( Kleinberg, L; Kut, C, 2023) |
| "Lymphopenia is known to precipitate dramatic elevation in serum BLyS; however, the use of this effect to enhance humoral responses following vaccination has not been evaluated." | 5.39 | BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. ( Archer, GE; Bigner, DD; Choi, BD; Heimberger, AB; Herndon, JE; Mitchell, DA; Norberg, P; Reap, EA; Sampson, JH; Sanchez-Perez, L; Sayour, EJ; Schmittling, RJ, 2013) |
| " We report that the lymphopenia induced by the chemotherapeutic agent temozolomide (TMZ) enhances vaccine-driven immune responses and significantly reduces malignant growth in an established model of murine tumorigenesis." | 5.15 | Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. ( Archer, GE; Bigner, DD; Congdon, KL; Cui, X; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; McLendon, RE; Mitchell, DA; Reardon, DA; Sampson, JH; Sanchez-Perez, L; Schmittling, RJ; Snyder, DJ; Vredenburgh, JJ, 2011) |
| "Temozolomide is an oral alkylating agent with established antitumor activity in patients with primary brain tumors and melanoma." | 4.86 | Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. ( Hwu, WJ; Neyns, B; Reardon, DA; Tosoni, A, 2010) |
| "Patients with glioblastoma (GBM) are treated with radiotherapy (RT) and temozolomide (TMZ)." | 4.12 | Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models. ( Campian, JL; Chheda, MG; Ferrando-Martinez, S; Ghosh, S; Hallahan, D; Hu, T; Jash, A; Kapoor, V; Lee, BH; Mahadevan, A; Page, L; Rifai, K; Thotala, D; Thotala, S; Wolfarth, AA; Yan, R; Yang, SH, 2022) |
| "Myelosuppression is the major toxicity encountered during temozolomide chemoradiotherapy for newly diagnosed glioblastoma." | 4.12 | Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. ( Chinot, O; Gorlia, T; Le Rhun, E; Nabors, B; Oppong, FB; Preusser, M; Stupp, R; Vanlancker, M; Weller, M; Wick, W, 2022) |
| "A total of 210 patients with supratentorial/nonmetastatic glioblastoma were treated with radiation therapy (RT) plus temozolomide from 2007 to 2016 and had laboratory data on total lymphocyte counts." | 3.88 | Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma. ( Campian, JL; Chang, X; Fergus, S; Hallahan, D; Huang, J; Hui, C; Lin, AJ; Mullen, D; Rao, YJ; Rudra, S; Samson, P; Thotala, D; Tsien, C; Yang, D, 2018) |
| "Management of patients with glioblastoma (GBM) often includes radiation (RT) and temozolomide (TMZ)." | 3.83 | Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. ( Campian, JL; Gao, F; Govindan, A; Huang, J; Leong, J; Mendez, JS, 2016) |
| "Acute severe lymphopenia (ASL) frequently develops during radiation therapy (RT) and concurrent temozolomide (TMZ) for high-grade glioma (HGG) and is associated with decreased survival." | 3.81 | Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. ( Badiyan, SN; Campian, JL; Chicoine, MR; DeWees, TA; Dunn, G; Fergus, S; Huang, J; Kim, AH; Linette, G; Mullen, DF; Robinson, CG; Simpson, JR; Speirs, CK; Tran, DD, 2015) |
| "Malignant glioma patients treated with the golden standard therapy, focal radiotherapy plus concomitant daily temozolomide (radiotherapy/TMZ), often suffer severe lymphopenia." | 3.76 | Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment. ( Akutsu, H; Ishikawa, E; Matsumura, A; Nakai, K; Sakamoto, N; Takano, S; Tsuboi, K; Yamamoto, T, 2010) |
| "Temozolomide is utilized as a treatment for a variety of solid tumors and has been associated with the development of selective lymphopenia." | 3.74 | Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. ( Baden, LR; Kulke, MH; Michelini, A; Schwarzberg, AB; Sengupta, T; Stover, EH; Vincitore, M, 2007) |
| "The authors investigated the safety of 75 mg/m2 temozolomide for 21 days every 28 days in glioma patients." | 3.73 | Is protracted low-dose temozolomide feasible in glioma patients? ( Blatt, V; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Pasetto, L; Scopece, L; Tosoni, A, 2006) |
| "Standard schedule temozolomide (TMZ; daily for 5 days every 4 weeks) is often used in melanoma patients, but phase III data show that it is no more effective than standard dacarbazine." | 3.72 | Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. ( Chapman, PB; Foster, T; Krown, SE; Livingston, PO; Quinn, C; Sepkowitz, KA; Sohn, S; Su, YB; Williams, L; Wolchok, JD, 2004) |
| " In addition, OS, PFS and adverse event (AE) data on ndGBM and recurrent GBM (rGBM) were assessed." | 2.82 | Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis. ( Li, H; Ma, W; Qu, T; Wang, Y; Wu, J; Xia, Y; Xing, H; Zhao, B, 2022) |
| "Bortezomib was administered on days 2, 5, 9, and 12; temozolomide on days 1-5 of a 28-day cycle." | 2.77 | A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. ( Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P, 2012) |
| "Temozolomide (TMZ) has shown modest efficacy in the treatment of recurrent brain metastasis (BM)." | 2.72 | Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. ( Abrey, LE; Demopoulos, A; Malkin, MG; Omuro, AM; Raizer, JJ, 2006) |
| "For a cytotoxic cancer-treatment agent, TMZ has an acceptable safety profile." | 2.45 | The safety of temozolomide in the treatment of malignancies. ( Hwu, WJ; Patel, SP; Trinh, VA, 2009) |
| "There is no standard treatment for glioblastoma with elements of PNET (GBM-PNET)." | 1.43 | Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. ( Fersht, N; Mandeville, HC; Mycroft, J; O'Leary, B; Saran, F; Solda, F; Vaidya, S; Zacharoulis, S, 2016) |
| "Temozolomide (TMZ) is an alkylating agent shown to prolong survival in patients with high grade glioma and is routinely used to treat melanoma brain metastases." | 1.39 | Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. ( Archer, GE; Bigner, DD; Choi, BD; Cui, X; Flores, C; Herndon, JE; Johnson, LA; Mitchell, DA; Sampson, JH; Sanchez-Perez, LA; Schmittling, RJ; Snyder, D, 2013) |
| "Lymphopenia is known to precipitate dramatic elevation in serum BLyS; however, the use of this effect to enhance humoral responses following vaccination has not been evaluated." | 1.39 | BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. ( Archer, GE; Bigner, DD; Choi, BD; Heimberger, AB; Herndon, JE; Mitchell, DA; Norberg, P; Reap, EA; Sampson, JH; Sanchez-Perez, L; Sayour, EJ; Schmittling, RJ, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (33.33) | 29.6817 |
| 2010's | 12 (40.00) | 24.3611 |
| 2020's | 8 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Campian, JL | 4 |
| Ghosh, S | 1 |
| Kapoor, V | 1 |
| Yan, R | 1 |
| Thotala, S | 1 |
| Jash, A | 1 |
| Hu, T | 1 |
| Mahadevan, A | 1 |
| Rifai, K | 1 |
| Page, L | 1 |
| Lee, BH | 1 |
| Ferrando-Martinez, S | 1 |
| Wolfarth, AA | 1 |
| Yang, SH | 1 |
| Hallahan, D | 2 |
| Chheda, MG | 1 |
| Thotala, D | 2 |
| Le Rhun, E | 1 |
| Oppong, FB | 1 |
| Vanlancker, M | 1 |
| Stupp, R | 1 |
| Nabors, B | 1 |
| Chinot, O | 1 |
| Wick, W | 2 |
| Preusser, M | 1 |
| Gorlia, T | 1 |
| Weller, M | 2 |
| Zhao, B | 1 |
| Wu, J | 1 |
| Xia, Y | 1 |
| Li, H | 1 |
| Wang, Y | 2 |
| Qu, T | 1 |
| Xing, H | 1 |
| Ma, W | 1 |
| Shi, DD | 1 |
| Youssef, GC | 1 |
| Nassar, AH | 1 |
| Lim-Fat, MJ | 1 |
| Ligon, KL | 1 |
| Wen, PY | 1 |
| Rahman, R | 1 |
| Garzio, K | 1 |
| McElroy, K | 1 |
| Grossman, S | 1 |
| Holdhoff, M | 1 |
| Ozer, B | 1 |
| Yankulina, O | 1 |
| Kut, C | 1 |
| Kleinberg, L | 1 |
| Tanriverdi, O | 1 |
| Hotchkiss, KM | 1 |
| Sampson, JH | 5 |
| Kanemura, Y | 1 |
| Sumida, M | 1 |
| Okita, Y | 1 |
| Yoshioka, E | 1 |
| Yamamoto, A | 1 |
| Kanematsu, D | 1 |
| Handa, Y | 1 |
| Fukusumi, H | 1 |
| Inazawa, Y | 1 |
| Takada, AI | 1 |
| Nonaka, M | 1 |
| Nakajima, S | 1 |
| Mori, K | 1 |
| Goto, S | 1 |
| Kamigaki, T | 1 |
| Shofuda, T | 1 |
| Moriuchi, S | 1 |
| Yamasaki, M | 1 |
| Rudra, S | 1 |
| Hui, C | 1 |
| Rao, YJ | 1 |
| Samson, P | 1 |
| Lin, AJ | 1 |
| Chang, X | 1 |
| Tsien, C | 1 |
| Fergus, S | 2 |
| Mullen, D | 1 |
| Yang, D | 1 |
| Huang, J | 3 |
| Sanchez-Perez, LA | 1 |
| Choi, BD | 2 |
| Archer, GE | 4 |
| Cui, X | 2 |
| Flores, C | 1 |
| Johnson, LA | 1 |
| Schmittling, RJ | 3 |
| Snyder, D | 1 |
| Herndon, JE | 4 |
| Bigner, DD | 4 |
| Mitchell, DA | 4 |
| Sanchez-Perez, L | 2 |
| Reap, EA | 1 |
| Sayour, EJ | 1 |
| Norberg, P | 1 |
| Heimberger, AB | 2 |
| DeWees, TA | 1 |
| Badiyan, SN | 1 |
| Speirs, CK | 1 |
| Mullen, DF | 1 |
| Tran, DD | 1 |
| Linette, G | 1 |
| Chicoine, MR | 1 |
| Kim, AH | 1 |
| Dunn, G | 1 |
| Simpson, JR | 1 |
| Robinson, CG | 1 |
| Mendez, JS | 1 |
| Govindan, A | 1 |
| Leong, J | 1 |
| Gao, F | 1 |
| O'Leary, B | 1 |
| Mandeville, HC | 1 |
| Fersht, N | 1 |
| Solda, F | 1 |
| Mycroft, J | 1 |
| Zacharoulis, S | 1 |
| Vaidya, S | 1 |
| Saran, F | 1 |
| Zwinkels, H | 1 |
| Roon, K | 1 |
| Jeurissen, FJ | 1 |
| Taphoorn, MJ | 1 |
| Hop, WC | 1 |
| Vecht, CJ | 1 |
| Trinh, VA | 1 |
| Patel, SP | 1 |
| Hwu, WJ | 2 |
| Neyns, B | 1 |
| Tosoni, A | 3 |
| Reardon, DA | 3 |
| Ishikawa, E | 1 |
| Yamamoto, T | 1 |
| Sakamoto, N | 1 |
| Nakai, K | 1 |
| Akutsu, H | 1 |
| Tsuboi, K | 1 |
| Takano, S | 1 |
| Matsumura, A | 1 |
| Aldape, KD | 1 |
| Coan, A | 1 |
| Desjardins, A | 2 |
| Friedman, AH | 2 |
| Friedman, HS | 2 |
| Gilbert, MR | 1 |
| McLendon, RE | 2 |
| Sawaya, R | 1 |
| Schmittling, R | 1 |
| Shi, W | 1 |
| Vredenburgh, JJ | 2 |
| Snyder, DJ | 1 |
| Congdon, KL | 1 |
| Portnow, J | 1 |
| Frankel, P | 1 |
| Koehler, S | 1 |
| Twardowski, P | 1 |
| Shibata, S | 1 |
| Martel, C | 1 |
| Morgan, R | 1 |
| Cristea, M | 1 |
| Chow, W | 1 |
| Lim, D | 1 |
| Chung, V | 1 |
| Reckamp, K | 1 |
| Leong, L | 1 |
| Synold, TW | 1 |
| Gajewski, TF | 1 |
| Su, YB | 1 |
| Sohn, S | 1 |
| Krown, SE | 1 |
| Livingston, PO | 1 |
| Wolchok, JD | 1 |
| Quinn, C | 1 |
| Williams, L | 1 |
| Foster, T | 1 |
| Sepkowitz, KA | 1 |
| Chapman, PB | 1 |
| Cavallo, G | 2 |
| Ermani, M | 2 |
| Scopece, L | 1 |
| Franceschi, E | 2 |
| Ghimenton, C | 1 |
| Gardiman, M | 1 |
| Pasetto, L | 1 |
| Blatt, V | 2 |
| Brandes, AA | 2 |
| Omuro, AM | 1 |
| Raizer, JJ | 1 |
| Demopoulos, A | 1 |
| Malkin, MG | 1 |
| Abrey, LE | 1 |
| Wong, ET | 1 |
| Bertorelle, R | 1 |
| Gioia, V | 1 |
| Biscuola, M | 1 |
| Crinò, L | 1 |
| Schwarzberg, AB | 1 |
| Stover, EH | 1 |
| Sengupta, T | 1 |
| Michelini, A | 1 |
| Vincitore, M | 1 |
| Baden, LR | 1 |
| Kulke, MH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide[NCT03687957] | Phase 1/Phase 2 | 70 participants (Anticipated) | Interventional | 2019-01-04 | Recruiting | ||
| A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII[NCT00643097] | Phase 2 | 40 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| REGULATory T-Cell Inhibition With Basiliximab (Simulect®) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme[NCT00626483] | Phase 1 | 34 participants (Actual) | Interventional | 2007-04-24 | Completed | ||
| A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors[NCT00544284] | Phase 1 | 25 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Time in months from the start of study treatment to the date of first progression according to Macdonald criteria, or to death due to any cause. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median PFS was estimated using a Kaplan-Meier curve.~Macdonald criteria are standard criteria in neuro-oncology. Tumor assessment was made according to the adapted MacDonald criteria based on the combined evaluation of: 1) assessment of the MRI scan for measurable, evaluable, and new lesions (made by the independent external expert too), 2) overall assessment of neurological performance (made by the investigator), 3) concomitant steroid use (as reported by the investigator)." (NCT00643097)
Timeframe: 58 months
| Intervention | months (Median) |
|---|---|
| Arm I (ACTIVATE) | 14.2 |
| Arm II (ACT II STD) | 12.1 |
| Arm III (ACT II DI) | 11.6 |
Number of patients that developed a delayed-type hypersensitivity (DTH) response at following vaccination. Any skin reaction in response to the intradermal injection of the antigen was measured and recorded. A positive skin test was defined as > 5 mm induration (swelling). (NCT00643097)
Timeframe: 26 months
| Intervention | participants (Number) |
|---|---|
| Arm I (ACTIVATE) | 3 |
| Arm II (ACT II STD) | 0 |
| Arm III (ACT II DI) | 7 |
The objective is to assess the duration of immunosuppressive cytokine secretion and to identify a receptive interval for active immunotherapy. Immunosuppression will determined by monitoring a panel of immunosuppressive serum/plasma cytokines longitudinally and by determining the response of each patient to Recombivax Hepatitis B (HB) vaccination. Response is defined as seropositive or seronegative to the Hepatitis B surface antigen. (NCT00643097)
Timeframe: 26 months
| Intervention | Months (Mean) |
|---|---|
| Arm I (ACTIVATE) | NA |
| Arm II (ACT II STD) | NA |
| Arm III (ACT II DI) | NA |
To assess for any potential toxicity to the PEP-3 vaccine immunization in patients with newly diagnosed glioblastoma, Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 was used to tabulate any toxicities attributable to PEP-3. The number of patients with toxicity attributable to vaccine while on study are tabulated. (NCT00643097)
Timeframe: 26 months
| Intervention | participants (Number) |
|---|---|
| Arm I (ACTIVATE) | 4 |
| Arm II (ACT II STD) | 1 |
| Arm III (ACT II DI) | 7 |
5 reviews available for temozolomide and Lymphopenia
| Article | Year |
|---|---|
Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis.
Topics: Aged; Antineoplastic Agents, Alkylating; Bayes Theorem; Brain Neoplasms; Dacarbazine; Glioblastoma; | 2022 |
Radiotherapy, lymphopenia and improving the outcome for glioblastoma: a narrative review.
Topics: Brain Neoplasms; Glioblastoma; Humans; Lymphopenia; Radiotherapy; Temozolomide; Treatment Outcome | 2023 |
Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Immunoth | 2021 |
The safety of temozolomide in the treatment of malignancies.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; | 2009 |
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
Topics: Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Drug Adm | 2010 |
5 trials available for temozolomide and Lymphopenia
| Article | Year |
|---|---|
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2011 |
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Topics: Adult; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Al | 2011 |
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Are | 2012 |
Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 2006 |
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Constipation; Dacarbazine; | 2006 |
20 other studies available for temozolomide and Lymphopenia
| Article | Year |
|---|---|
Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.
Topics: Animals; Brain Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Clinical Trials, Phase I as | 2022 |
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; | 2022 |
Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lymphopenia; Temozolomide | 2022 |
Safety of temozolomide use in adult patients with renal dysfunction.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Kidney Disea | 2022 |
Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak.
Topics: Antineoplastic Agents, Alkylating; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Immuno | 2020 |
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Brain Neoplasms; Cell Line, Tumor; Child; Daca | 2017 |
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bevacizumab; Carmu | 2018 |
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
Topics: Animals; Antigens; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; CD8-Positive | 2013 |
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
Topics: Antibodies; Antibody Specificity; Antineoplastic Agents, Alkylating; B-Cell Activating Factor; Cance | 2013 |
Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain | 2015 |
Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2016 |
Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemothera | 2016 |
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; D | 2009 |
Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2010 |
Temozolomide for melanoma: new toxicities and new opportunities.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Humans; Lymphopenia; M | 2004 |
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; Dacar | 2004 |
How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Lymphopenia; Neoplasm Recurren | 2005 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Dose- | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Combined Modal | 2006 |
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Female; Her | 2007 |